Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

Miguel Martín; Álvaro Rodríguez-Lescure; Amparo Ruiz; Emilio Alba; Lourdes Calvo; Manuel Ruiz-Borrego; Ana Santaballa; César A. Rodríguez; Carmen Crespo; Mar Abad; Severina Domínguez; Jesús Florián; Cristina Llorca; Miguel Méndez; María Godes; Ricardo Cubedo; Adolfo Murias; Norberto Batista; María José García; Rosalía Caballero; Enrique de Álava

doi:10.1007/s10549-009-0663-z

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-009-0663-z ◽

2009 ◽

Vol 123 (1) ◽

pp. 149-157 ◽

Cited By ~ 47

Author(s):

Miguel Martín ◽

Álvaro Rodríguez-Lescure ◽

Amparo Ruiz ◽

Emilio Alba ◽

Lourdes Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Weekly Paclitaxel

Download Full-text

Cost effectiveness and tolerability of dose dense versus weekly paclitaxel chemotherapy in patients with early breast cancer: A real-world comparison.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e18264 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e18264-e18264

Author(s):

Wanyi Kee ◽

Raimundas Galiauskas ◽

Brian Richard Bird ◽

Kate Murphy ◽

James Cook ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Real World ◽

Weekly Paclitaxel ◽

Dose Dense

Download Full-text

Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.518 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 518-518 ◽

Cited By ~ 5

Author(s):

Ulrike Nitz ◽

Oleg Gluz ◽

Matthias Christgen ◽

Eva-Maria Grischke ◽

Doris Augustin ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Predictive Markers ◽

Weekly Paclitaxel ◽

Dual Blockade

Download Full-text

Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity.

10.1158/0008-5472.sabcs-09-3088 ◽

2009 ◽

Author(s):

P. Morris ◽

C. Chen ◽

N. Lin ◽

B. Moy ◽

S. Come ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Troponin I ◽

Weekly Paclitaxel ◽

C Reactive Protein ◽

Reactive Protein ◽

Dose Dense

Download Full-text

Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting

Breast Cancer ◽

10.1007/s12282-014-0564-9 ◽

2014 ◽

Vol 23 (2) ◽

pp. 261-265 ◽

Cited By ~ 1

Author(s):

Iuri A. Santana ◽

Julia Andrade Oliveira ◽

Julianne Maria da Silva Lima ◽

Laura Testa ◽

José Roberto M. Piato ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Community Setting ◽

Weekly Paclitaxel

Download Full-text

Neoadjuvant pertuzumab, T-DM1, weekly paclitaxel and possible anthracyclines in HER2 positive early breast cancer treatment—questions from the KRISTINE study

Translational Cancer Research ◽

10.21037/tcr.2018.04.14 ◽

2018 ◽

Vol 7 (S5) ◽

pp. S562-S567

Author(s):

Jack P. Gleeson ◽

Niamh M. Keegan ◽

Patrick G. Morris

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Early Breast Cancer ◽

Breast Cancer Treatment ◽

Weekly Paclitaxel ◽

Her2 Positive

Download Full-text

160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.282 ◽

2020 ◽

Vol 31 ◽

pp. S303-S304

Author(s):

A. Schneeweiss ◽

V. Möbus ◽

H. Tesch ◽

P. Klare ◽

C. Denkert ◽

...

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

High Risk ◽

Neoadjuvant Chemotherapy ◽

Early Breast Cancer ◽

Triple Negative Breast Cancer ◽

Liposomal Doxorubicin ◽

Triple Negative ◽

Phase Iii ◽

Weekly Paclitaxel

Download Full-text

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of Oncology ◽

10.1093/annonc/mdx494 ◽

2017 ◽

Vol 28 (11) ◽

pp. 2768-2772 ◽

Cited By ~ 33

Author(s):

U.A. Nitz ◽

O. Gluz ◽

M. Christgen ◽

E. -M. Grischke ◽

D. Augustin ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Predictive Markers ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Dual Blockade

Download Full-text

Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”

Annals of Oncology ◽

10.1016/j.annonc.2021.12.008 ◽

2022 ◽

Author(s):

U.A. Nitz ◽

O. Gluz ◽

M. Christgen ◽

E.-M. Grischke ◽

D. Augustin ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Predictive Markers ◽

Weekly Paclitaxel ◽

Her2 Positive ◽

Dual Blockade

Download Full-text

Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy

Supportive Care in Cancer ◽

10.1007/s00520-018-4087-3 ◽

2018 ◽

Vol 26 (7) ◽

pp. 2471-2477 ◽

Cited By ~ 2

Author(s):

Napa Parinyanitikul ◽

Walailuk Tanpipattanakul ◽

Nattaya Poovorawan ◽

Thanapoom Rattananupong ◽

Poranee Laoitthi ◽

...

Keyword(s):

Breast Cancer ◽

Hypersensitivity Reaction ◽

Cancer Patients ◽

Early Breast Cancer ◽

Weekly Paclitaxel ◽

Breast Cancer Patients

Download Full-text

Breast conserving therapy for early breast cancer. Brachytherapy or proton beam boost: a randomized study

European Journal of Cancer ◽

10.1016/s0959-8049(02)80498-1 ◽

2002 ◽

Vol 38 (11) ◽

pp. S149

Author(s):

M Greco

Keyword(s):

Breast Cancer ◽

Proton Beam ◽

Early Breast Cancer ◽

Randomized Study ◽

Breast Conserving Therapy

Download Full-text